Supply Chain

Lack of trust in pharma-provided content proves to be a key barrier to successful engagement, highlighting issues like promotional spin, information availability, and more.

Law aims to mitigate ongoing global drug shortages.

Researchers highlight steps to be taken in the European Union to manage the challenge of ongoing drug shortages.

IQVIA report explores why these shortages are increasing, and how they can be mitigated.

House Committee on Oversight and Accountability request documents on agency’s drug shortage mitigation strategies.

Due to a higher than anticipated demand, Sanofi is carefully managing distribution of 50 mg doses of Beyfortus in the private market to fulfill existing orders and provide equitable access to remaining doses for the vaccine that protects infants against respiratory syncytial virus.

Mangal discusses the causes of the shortage and how pharma companies can find solutions.

Due to a global demand, treatments such as Adderall and Ritalin have been in short supply for the management of attention-deficit hyperactivity disorder.

Increase in new treatments also brings increase in logistical challenges for pharma.

As borders shut down during the pandemic, pharma learned some lessons about sourcing.

The 2013 Drug Supply Chain Security Act (DSCSA) established a framework for exchanging data when products are transacted throughout the US pharma supply chain. Its goal, by November 2023, is to enable unit-level traceability in a secure, interoperable manner. HDA’s Chip Davis talks about how pharma manufacturers must prepare for this implementation deadline.

Rafael Teixeira on building an end-to-end cold chain strategy to support global storage and distribution efforts.

Additional assistance necessary for patients prescribed specialty therapies.

The Biden administration has rolled out a broad initiative to promote domestic production of critical materials, including medicines and their ingredients.

Hannah Schofield and Lavan Thasarathakumar discuss what blockchain is, how it could help improve pharmaceutical supply chains, and the COVID-19 vaccine supply chain in particular, and touches on where we are already seeing blockchain technology being used in this area.

To effectively combat the looming threat of antimicrobial resistance, we must prioritize working together to strengthen and more responsibly manage global supply chains.

If telehealth is here to stay, how is the industry adjusting?

Mitigating the risks of development, authorization, and marketing for new therapies following "new normal" created by COVID-related violations.

Ferdi Steinmann outlines a few supply chain lessons that all pharma companies can learn from the COVID-19 pandemic.

Taking stock of evolving practices in protecting the supply chain amid the pandemic, including partnering and planning for what’s next.

It is vital to begin asking questions about your company’s DSCSA readiness and compliance, as well as that of your strategic partners, writes Rob Besse.

MilliporeSigma's Robert McGuirk speaks with Pharma Exec about the role of supply chain robustness in helping to mitigate the risk of drug shortages

Coexisting with the DSCSA may hinder new legislative efforts.

How to navigate the production and reimbursement intricacies of bringing regenerative medicines from bench to bedside.

Tim Willis and Oliver Wack outline the role of alternative data in supply chain risk management, and the ancillary benefits that come from adopting such technology.

Pharm Exec’s annual look at what lies ahead for the biopharma industry in the coming months examines eight key trends that are seemingly at tipping points in their evolution and poised to shape the life sciences landscape in 2019.

The next generation of supply chain shows an increasing need for blockchain technology.

How low-cost drugs can succeed in the specialty pharmacy channel.

In today’s drug development environment, there is no doubt that supply chain decisions are paramount in a product launch strategy, writes Lisa Henderson.

With blockchain still in the potential but not proven area of the pharma enterprise, when is the technology the right choice for you?